Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation.

Kumar R, Tuen M, Li H, Tse DB, Hioe CE.

Vaccine. 2011 Nov 8;29(48):9064-74. doi: 10.1016/j.vaccine.2011.09.057. Epub 2011 Sep 23.

2.

Improving on nature: focusing the immune response on the V3 loop.

Zolla-Pazner S.

Hum Antibodies. 2005;14(3-4):69-72. Review.

PMID:
16720976
3.

Recent strategies targeting HIV glycans in vaccine design.

Horiya S, MacPherson IS, Krauss IJ.

Nat Chem Biol. 2014 Dec;10(12):990-9. doi: 10.1038/nchembio.1685. Review.

4.

Neutralizing antibodies to HIV-1 induced by immunization.

McCoy LE, Weiss RA.

J Exp Med. 2013 Feb 11;210(2):209-23. doi: 10.1084/jem.20121827. Review.

5.

Neutralizing antibodies mechanism of neutralization and protective activity against HIV-1.

Xiao Y, Dong X, Chen YH.

Immunol Res. 2002;25(3):193-200. Review.

PMID:
12018459
6.

Designing synthetic vaccines for HIV.

Fern√°ndez-Tejada A, Haynes BF, Danishefsky SJ.

Expert Rev Vaccines. 2015 Jun;14(6):815-31. doi: 10.1586/14760584.2015.1027690. Epub 2015 Mar 31. Review.

7.

HIV-1 vaccines: challenges and new perspectives.

Excler JL, Robb ML, Kim JH.

Hum Vaccin Immunother. 2014;10(6):1734-46. doi: 10.4161/hv.28462. Epub 2014 Mar 17. Review.

8.

HIV vaccine candidates.

Wu TT, Johnson G.

Drugs Today (Barc). 2004 Nov;40(11):949-55. Review.

PMID:
15645007
9.

Synthetic carbohydrate antigens for HIV vaccine design.

Wang LX.

Curr Opin Chem Biol. 2013 Dec;17(6):997-1005. Review.

10.

Receptor binding domain based HIV vaccines.

Liu H, Bi W, Wang Q, Lu L, Jiang S.

Biomed Res Int. 2015;2015:594109. doi: 10.1155/2015/594109. Epub 2015 Jan 15. Review.

11.

New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.

Musich T, Robert-Guroff M.

Expert Rev Vaccines. 2016 Aug;15(8):1015-27. doi: 10.1586/14760584.2016.1158108. Epub 2016 Mar 16. Review.

PMID:
26910195
12.
13.

Non-Neutralizing Antibodies Directed against HIV and Their Functions.

Mayr LM, Su B, Moog C.

Front Immunol. 2017 Nov 20;8:1590. doi: 10.3389/fimmu.2017.01590. eCollection 2017. Review.

14.
15.

Neutralization-Enhancing RF Antibodies for HIV Vaccines.

Suslov KV.

Front Immunol. 2014 Dec 16;5:634. doi: 10.3389/fimmu.2014.00634. eCollection 2014. Review. No abstract available.

16.

The importance of handling high-value biologicals: Physico-chemical instability and immunogenicity of monoclonal antibodies.

LaptoŇ° T, Omersel J.

Exp Ther Med. 2018 Apr;15(4):3161-3168. doi: 10.3892/etm.2018.5821. Epub 2018 Jan 31. Review.

Supplemental Content

Support Center